Patents Assigned to Wistar Institute
  • Method for identifying a compound that modulates SIR2 protein activity
    Patent number: 8180580
    Abstract: The present invention relates to a method for identifying compounds that modulate the activity of sirtuin deacetylase protein family members. Compounds of the invention are identified by designing or screening for a compound which binds to at least one amino acid residue of the newly identified nicotinamide inhibition and base exchange site of Sir2 and testing the compound for its ability to modulate the activity of the Sir2 protein. Compositions and methods for preventing or treating diseases or disorders associated with Sir2 are also provided.
    Type: Grant
    Filed: January 31, 2008
    Date of Patent: May 15, 2012
    Assignee: The Wistar Institute
    Inventors: Ronen Marmorstein, Brandi D. Sanders
  • Biocompatible, biodegradable polymer-based, lighter than or light as water scaffolds for tissue engineering and methods for preparation and use thereof
    Patent number: 8137972
    Abstract: Scaffolds for tissue engineering prepared from biocompatible, biodegradable polymer-based, lighter than or light as water microcarriers and designed for cell culturing in vitro in a rotating bioreactor are provided. Methods for preparation and use of these scaffolds as tissue engineering devices are also provided.
    Type: Grant
    Filed: May 30, 2007
    Date of Patent: March 20, 2012
    Assignees: Drexel University, The Wistar Institute, The Trustees Of The University of Pennsylvania
    Inventors: Cato T. Laurencin, Solomon R. Pollack, Elliot Levine, Edward Botchwey, Helen H. Lu, Mohammed Yusuf Khan
  • Metal complex phosphatidyl-inositol-3-kinase inhibitors
    Patent number: 8106039
    Abstract: Provided are novel organometallic compounds that inhibit PI3K lipid kinase and phospho-AKT in human melanoma cells, and also inhibit the migration of melanoma cells. The present invention is also directed to methods for inhibiting cancer cell proliferation, migration or both comprising contacting a cancer cell with a disclosed organometallic kinase inhibitor. Also disclosed are methods for treating a kinase-affected disease or condition comprising administering to a subject in need thereof a therapeutically effective amount of a disclosed organometallic kinase inhibitor.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: January 31, 2012
    Assignees: The Trustees Of The University Of Pennsylvania, The Wistar Institute Of Anatomy And Biology
    Inventors: Eric Meggers, Peng Xie, Douglas S. Williams, Ronen Marmorstein
  • MicroRNA Modulators and Method for Identifying And Using The Same
    Publication number: 20120010177
    Abstract: The present invention is a method for identifying agents which modulate microRNA activity. The invention involves contacting a cell harboring a microRNA and a microRNA binding sequence, which is operably linked to a nucleic acid molecule encoding a reporter protein, with a test agent and determining whether the test agent increases or decreases the expression of the reporter protein thereby identifying a microRNA modulator. Antagonists identified by this screening assay are provided, as are methods for using the same to inhibit microRNA activity and prevent or treat disease.
    Type: Application
    Filed: August 1, 2011
    Publication date: January 12, 2012
    Applicant: The Wistar Institute / North Carolina State University
    Inventors: Qihong Huang, Alexander Deiters, Kiranmai Gumireddy
  • Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer
    Publication number: 20110306662
    Abstract: The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.
    Type: Application
    Filed: June 15, 2011
    Publication date: December 15, 2011
    Applicant: The Wistar Institute and The Trustees of the University of Pennsylvania
    Inventors: Nadia Dahmane, Jeffrey D. Winkler
  • Treatment of melanoma using HSV mutant
    Patent number: 8067012
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Grant
    Filed: January 22, 2010
    Date of Patent: November 29, 2011
    Assignees: Crusade Laboratories Limited, The Wistar Institute
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Treatment of Non-Neuronal Cancer using HSV-1 Variants
    Publication number: 20110195053
    Abstract: A mutant herpes simplex virus which has been modified in the ?34.5 gene such that the gene is non-functional is used to treat a non-neuronal cancer such as a mesothelioma, ovarian carcinoma, bladder cancer or melanoma. Typically, the mutant herpes simplex virus has been modified within the BamHI restriction fragment of the long terminal repeat of the viral genome.
    Type: Application
    Filed: April 20, 2011
    Publication date: August 11, 2011
    Applicants: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, CRUSADE LABORATORIES LIMITED, WISTAR INSTITUTE
    Inventors: Susanne M. Brown, Alasdair R. Maclean, Nigel W. Fraser, Bruce P. Randazzo, Steven Albelda, Larry Kaiser, John Kucharczuk
  • TREATMENT OF METASTATIC TUMORS AND OTHER CONDITIONS
    Publication number: 20110064828
    Abstract: The present invention generally relates to pharmacology and, in particular, to the treatment of tumors and other conditions. In some aspects, the invention is directed to the treatment of subjects having tumors or cancers that are metastatic. Surprisingly, it has been found that certain compositions comprising oxidized glutathione-based compounds are able to effectively treat such cancers by inhibiting cell migration and/or invasion processes, and thus, inhibiting tumor cell metastases. Without being bound by any theory, it is believed that such compositions are effective since the compositions are able to suppress the activation of critical signaling pathways within cells that are used for cell migration, such as the ErbB2 and/or phosphoinositide-3 kinase (PI3K) pathways, including the downstream RhoA and AKT pathways.
    Type: Application
    Filed: September 10, 2010
    Publication date: March 17, 2011
    Applicants: Novelos Therapeutics, Incorporated, The Wistar Institute
    Inventors: Chris Pazoles, Evgeny Vulfson, Qihong Huang
  • Steroid-Derived Cyclopamine Analogs and Methods for Using the Same in the Prevention or Treatment of Cancer
    Publication number: 20100298281
    Abstract: The present invention relates to steroid-derived cyclopamine analogs and methods for using the same for inhibiting sonic hedgehog signaling and preventing or treating cancer. A method for synthesizing the analogs of the present invention from a steroid is also provided.
    Type: Application
    Filed: October 30, 2008
    Publication date: November 25, 2010
    Applicants: THE WISTAR INSTITUTE, THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: Nadia Dahmane, Jeffrey D. Winkler
  • RECOMBINANT VECTOR CONTAINING INFECTIOUS HUMAN CYTOMEGALOVIRUS GENOME WITH PRESERVED WILD-TYPE CHARACTERISTICS OF CLINICAL ISOLATES
    Publication number: 20100267121
    Abstract: A recombinant vector containing infectious genome of human cytomegalovirus (HCMV) and being useful for the production of reconstituted HCMV virus retaining phenotypic characteristics of a clinical virus isolate including the ability to grow on endothelial cells and to induce microfusion is characterized in that it is obtainable by inserting DNA from a clinical isolate of HCMV virus into a bacterial cloning vehicle. Such vector can be used e.g., for production of reconstituted HCMV virus retaining the phenotypic characteristics of a parental clinical isolate and for studying genes and functions of genes of HCMV virus. A further aspect are mutant viruses and inter alia their use for studying aspects of infectivity of HCMV virus.
    Type: Application
    Filed: December 11, 2009
    Publication date: October 21, 2010
    Applicants: Vical Incorporated, Wistar Institute
    Inventor: Gabriele Hahn
  • Methods and compositions for treating melanoma
    Patent number: 7811993
    Abstract: Novel BRAFV600E mutant peptides or a pharmaceutically acceptable salt thereof, that induce MHC Class I-dependent cytotoxic T cell responses in mammals are useful in prophylactic, diagnostic and therapeutic treatments for melanoma. Such compounds are also useful in drug development for non-peptide mimics of the compounds described herein and in the development of therapeutic or diagnostic antibodies.
    Type: Grant
    Filed: June 28, 2006
    Date of Patent: October 12, 2010
    Assignee: The Wistar Institute of Anatomy and Biology
    Inventors: Dorothee Herlyn, Rajasekaran Somasundaram, Laszlo Otvos, Jr.
  • METHOD FOR DIAGNOSING LUNG CANCERS USING GENE EXPRESSION PROFILES IN PERIPHERAL BLOOD MONONUCLEAR CELLS
    Publication number: 20100255486
    Abstract: Methods and compositions are provided for diagnosing lung cancer in a mammalian subject by use of three or more selected genes, e.g., a gene expression profile, from the peripheral blood mononuclear cells (PBMC) of the subject which is characteristic of disease, a stage of the disease, or enables prognosis of recurrence of disease. The gene expression profile includes three or more genes of Table I, Table II, Table III, Table IV, Table V, Table VI or Table VII herein. Detection of changes in expression in the selected genes forming the gene expression profile from that of a reference gene expression profile are correlated with non-small cell lung cancer (NSCLC). One composition for use in such diagnosis includes three or more PCR primer-probe sets, wherein each primer-probe set amplifies a different polynucleotide sequence from the gene expression profile.
    Type: Application
    Filed: December 5, 2008
    Publication date: October 7, 2010
    Applicants: The Wistar Institute of Anatomy and Biology, The Trustees of the University of Pennsylvania
    Inventors: Michael Showe, Louise Showe, Malik Yousef, Steven M. Albelda, Anil Vachani, Andrei V. Kossenkov
  • Treatment of Cancer Using HSV Mutant
    Publication number: 20100172872
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Application
    Filed: January 22, 2010
    Publication date: July 8, 2010
    Applicants: CRUSADE LABORATORIES LIMITED, THE WISTAR INSTITUTE
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Composition and method for preventing or treating a virus infection
    Patent number: 7740860
    Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.
    Type: Grant
    Filed: March 13, 2006
    Date of Patent: June 22, 2010
    Assignee: The Wistar Institute
    Inventors: Walter Gerhard, Laszlo Otvos, Jr.
  • BRAF35 protein and BRCA2/BRAF35 complex and methods of use
    Patent number: 7691976
    Abstract: An isolated nucleic acid sequence of BRAF35 and polypeptides encoded thereby are provided, as well as a multiprotein complex, and an antibody capable of binding selectively to the BRAF35 protein. Related agents and compositions which modulate interaction between BRCA2 and BRAF35 and methods of their use for screening for the BRCA2 protein, suppressing tumors and identifying DNA damage in cells indicative of a risk for developing cancer are also provided.
    Type: Grant
    Filed: November 13, 2001
    Date of Patent: April 6, 2010
    Assignee: The Wistar Institute
    Inventor: Ramin Shiekhattar
  • Treatment of cancer using HSV mutant
    Patent number: 7674468
    Abstract: Use as an anti-cancer agent of a mutant herpes simplex virus wherein the mutant virus comprises a modification in the ?34.5 gene in the long repeat region (RL) such that the ?34.5 gene is a non-functional, manufacture of medicaments and methods of testing cancer in mammals employing HSV mutant.
    Type: Grant
    Filed: June 13, 2005
    Date of Patent: March 9, 2010
    Assignees: Crusade Laboratories Limited, The Wistar Institute
    Inventors: Alasdair Roderick MacLean, Susanne Moira Brown, Nigel William Fraser, Bruce Paul Randazzo
  • Peptides and peptidomimetics with structural similarity to human p53 that activate p53 function
    Patent number: 7666983
    Abstract: The present invention provides peptides and peptidomimetics corresponding to part or to the entirety of the region encompassed by residues 360-386 of human p53, said peptides and peptidomimetics characterized by the ability to activate DNA binding of wild-type p53 and of select tumor-derived p53 mutants. Pharmaceutical compositions of the compounds of the invention and methods of using these compositions therapeutically are also provided.
    Type: Grant
    Filed: March 9, 2007
    Date of Patent: February 23, 2010
    Assignees: Bayer Healthcare LLC, The Wistar Institute
    Inventors: Thanos Halazonetis, Wolfgang Hartwig
  • Method of diagnosis of cancer based on gene expression profiles in cells
    Patent number: 7640114
    Abstract: A method of developing a gene expression profile indicative of the presence or stage of a selected a disease, disorder or genetic pathology in a mammalian subject employs penalized discriminant analysis with recursive feature elimination. A method of diagnosing a cancer in a mammalian subject includes the steps of examining a sample containing the subject's immune cells and detecting a variance in the expression of a statistically significant number of genes, e.g., at least 10 non-tumor genes from those same genes in a characteristic disease or healthy gene expression profile. A significant variance in expression of these genes when compared to a gene expression profile, preferably an average gene expression profile of a normal control, or significant similarities to an average gene profile of subjects with cancer, correlates with a specific type of cancer and/or location of tumor.
    Type: Grant
    Filed: May 21, 2004
    Date of Patent: December 29, 2009
    Assignee: The Wistar Institute of Anatomy & Biology
    Inventors: Louise C. Showe, Michael K. Showe, Laszlo Kari, Michael Nebozhyn, Andrey Loboda
  • Methods and compositions for monitoring cell migration and identifying clinically relevant cytotoxic T lymphocyte activity
    Patent number: 7544465
    Abstract: A three-dimensional reconstruct model containing solid layers of collagen and fibroblasts closely mimic the condition of patients in vivo, preserving in vivo phenotypic and functional characteristics of the cells. Reconstructs can be used to detect cellular migration, including active migration of cytotoxic T lymphocytes towards tumor cells, which can be measured by detecting tumor cell lysis. Reconstructs also can be used to identify factors that influence migration of cells, including chemokines that influence migration of cytotoxic T lymphocytes, as well as to identify tumor antigens.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: June 9, 2009
    Assignee: The Wistar Institute
    Inventors: Dorothee Herlyn, Meenhard Herlyn, Rajasckharan Somasundaram
  • Composition and method for preventing or treating a virus infection
    Patent number: 7527798
    Abstract: The present invention provides multiple antigenic agents compositions and the use thereof to prevent or treat viral infections.
    Type: Grant
    Filed: January 14, 2004
    Date of Patent: May 5, 2009
    Assignee: The Wistar Institute
    Inventors: Walter Gerhard, Laslo Otvos